Wegovy and Medicare: Complete 2026 Coverage Guide

This guide is the practical companion to the coverage rules: not just whether Wegovy and Medicare work together in 2026, but how to set up your enrollment, paperwork, and pharmacy so the claim actually pays.

Wegovy works with Medicare two ways in 2026. Beneficiaries with established cardiovascular disease have had Part D coverage since 2024 under the heart-protection indication. Everyone else gains a path on July 1, 2026, when the Medicare GLP-1 Bridge pilot opens weight-management coverage with $50 monthly copay caps and a $245 government-negotiated price. Getting paid requires the right plan, the right documentation, and the right timing, all covered step by step below.

If you want the policy background and news timeline, read our companion guide on whether Medicare covers Wegovy. This page is the checklist.

Step 1: Confirm You Have the Right Kind of Medicare

Wegovy coverage is through prescription drug benefits – which is Part D – either through an Original Medicare plan with a Part D option or through a Medicare Advantage plan that also covers drugs (most do). Without a drug plan, Original Medicare will pay for nothing at the pharmacy.

Be sure to look for Wegovy in your plan's formulary using Medicare.gov's plan finder. If it's not available in your plan, make sure to know that the Bridge pilot works in the context of Part D plans, and the fall open enrollment period (October 15 to December 7) will be the time to switch to another plan if your plan treats the pilot poorly.

Step 2: Match Your Diagnosis to the Right Pathway

Take this to your appointment with your doctor. Today, anyone who has had a heart attack, stroke, or peripheral arterial disease and has a BMI of 27 or higher is eligible for the cardiovascular indication. Your prescriber makes a referral for prior authorization based on your cardiac history.

For those who are qualified for weight, this is the Bridge pilot, which begins July 1st, 2026, for patients with either prediabetes or heart disease (as documented on their chart) with a BMI of 27 or more. Already using Wegovy for self-pay? Pick up your starting-weight records now, because even though you lose weight, so long as you met the criteria at the start of therapy you remain eligible, as NPR explained in its Bridge explainer.

Step 3: Build the Prior Authorization File

All pathways must go through the prior authorization process and full files turn around in days, whereas thin files bounce for weeks. Your prescriber will need to add: current BMI and weight history, qualifying diagnosis and dates (cardiac event records or prediabetes labs), your current list of medications and confirm no other GLP-1s, and if you are a Bridge continuation patient, your attestation of baseline eligibility.

Standard Delivery Time for decisions is 72 hours, expedited delivery is 24 hours. Schedule the expiration date for authorization the following day after it is approved; renewals usually require proof that the medication is effective, usually a 5% reduction in weight from baseline.

Step 4: Know Your Numbers at the Pharmacy

Under the November 2025 federal pricing agreement, Medicare pays $245 monthly for Wegovy and your copay caps at $50. Plan deductibles up to $615 can apply to early fills, and once your total covered drug spending reaches $2,100 for the year, you pay nothing further. Both the injectable and the new oral pill follow the same structure.

If a fill rejects, don't pay list price at the counter. Common fixes: the authorization lapsed (renew it), the pharmacy billed the wrong form (pill vs pen), or the plan needs the Bridge enrollment flag. NovoCare's $499 self-pay price is the stopgap while paperwork resolves, never the long-term plan.

What to Do if You're Denied

Medicare appeals move fast when you push them. A redetermination request gets an answer within 7 days (72 hours expedited). Most Wegovy denials trace to missing cardiac documentation, an unflagged Bridge enrollment, or BMI records absent from the file, all fixable on resubmission. If the plan upholds the denial, an Independent Review Entity takes the second look, and prescriber letters of medical necessity win these regularly when the clinical criteria are genuinely met.